Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation

AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC(50)] = 0.08 to 0.27 μM; EC(90) = 0.33 to 1.32 μM) with no sign...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Mani, Nagraj, Cole, Andrew G., Phelps, Janet R., Ardzinski, Andrzej, Cobarrubias, Kyle D., Cuconati, Andrea, Dorsey, Bruce D., Evangelista, Ellen, Fan, Kristi, Guo, Fang, Guo, Haitao, Guo, Ju-Tao, Harasym, Troy O., Kadhim, Salam, Kultgen, Steven G., Lee, Amy C. H., Li, Alice H. L., Long, Quanxin, Majeski, Sara A., Mao, Richeng, McClintock, Kevin D., Reid, Stephen P., Rijnbrand, Rene, Snead, Nicholas M., Micolochick Steuer, Holly M., Stever, Kim, Tang, Sunny, Wang, Xiaohe, Zhao, Qiong, Sofia, Michael J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2018
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971612/
https://ncbi.nlm.nih.gov/pubmed/29555628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00082-18
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge